Drug therapy for interstitial lung disease

Diffuse Lung Disease: A Practical Approach: Second Edition

Volumn 9781441997715, Issue , 2012, Pages 101-120

  Baughman, Robert P ^a   Costabel, Ulrich ^b   Lower, Elyse E ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RUHRLANDKLINIK   (Germany)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Azathioprine; Cyclophosphamide; Infliximab; Leflunomide; Methotrexate; Mycophenolate; Prednisone; Rituximab

Indexed keywords

EID: 84948979509     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9771-5_7     Document Type: Chapter

References (164)

1. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142:1268-71.
2. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283-6.
3. Webster JC, Oakley RH, Jewell CM, et al. Proinfl ammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA. 2001;98(12): 6865-70.
4. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29(3):533-48.
5. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fl uticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19(3):198-204.
6. Flaherty KR, Toews GB, Lynch III JP, et al. Steroids in idiopathic pulmonary fi brosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med. 2001;110(4):278-82.
7. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60-6.
8. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954-63.
9. Coulson KA, Reed G, Gilliam BE, et al. Factors infl uencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15(4):155-60.
10. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997; 61(5):382-5.
11. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385-92.
12. Chan ES, Cronstein BN. Molecular action of methotrexate in infl ammatory diseases. Arthritis Res. 2002; 4(4):266-73.
13. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54: 742-6.
14. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more effi cacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36(1):86-90.
15. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008; 359(26):2790-803.
16. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833-41.
17. Kremer JM, Alarcon GS, Lightfoot Jr. RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994; 37(3):316-28.
18. Roenigk HH, Auerbach R, Mailbach HI, et al. Methotrexate guidelines revised. J Am Acad Dermatol. 1982;6:145-55.
19. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexateinduced liver damage in sarcoidosis. Arch Intern Med. 2003;163(5):615-20.
20. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002;8(5):470-6.
21. Zisman DA, McCune WJ, Tino G, et al. Druginduced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3): 243-52.
22. Schnabel A, Richter C, Bauerfeind S, et al. Bronchoalveolar lavage cell profi le in methotrexate pneumonitis. Thorax. 1997;52:377-9.
23. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis. 1997;14:121-30.
24. Baughman RP, Lower EE. Lefl unomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43-8.
25. Rustin GJS, Rustin F, Dent J, et al. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med. 1982;308:473-6.
26. Balin PL, Tindall JP, Roenigk HH, et al. Is methotrexate therapy for psoriasis carcinogenic? A modifi ed retrospective-prospective analysis. JAMA. 1975;232:359-62.
27. Alcorn N, Saunders S, Madhok R. Benefi t-risk assessment of lefl unomide: an appraisal of lefl unomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123-34.
28. Chan V, Tett SE. How is lefl unomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf. 2006;15(7):485-93.
29. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the effiffcacy and safety of lefl unomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655-65.
30. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant lefl unomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebocontrolled trial. Ann Intern Med. 2002;137(9): 726-33.
31. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus lefl unomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46(7): 1087-91.
32. Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with lefl unomide: a profi le of New Zealand and Australian reports. Intern Med J. 2006; 36(3):162-9.
33. Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with lefl unomide: is there a risk patient profi le? Pharmacoepidemiol Drug Saf. 2007;16(1):74-8.
34. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fi brosis: a prospective doubleblind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144(2):291-6.
35. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/ prednisolone regimen. Eur Respir J. 1999; 14(5):1117-22.
36. Cooper SC, Ford LT, Berg JD, et al. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics. 2008;9(3):303-9.
37. Perri D, Cole DE, Friedman O, et al. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J. 2007;30(5):1014-7.
38. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with infl ammatory bowel disease. Aliment Pharmacol Ther. 2007;25(9):1069-77.
39. Ansari A, Arenas M, Greenfi eld SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of infl ammatory bowel disease. Aliment Pharmacol Ther. 2008;28(8):973-83.
40. McKendry RJR, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients. Arch Intern Med. 1989;149:685-9.
41. Kehinde EO, Petermann A, Morgan JD, et al. Triple therapy and incidence of de nova cancer in renal transplants. Br J Surg. 1994;81:985-6.
42. Mackenzie KA, Wells JE, Lynn KL, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant. 2010; 25(1):300-6.
43. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008; 14(3):399-405.
44. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular infl ammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480. doi: 10.1136/bmj.b2480.:b2480 .
45. Caspersen S, Elkjaer M, Riis L, et al. Infl iximab for infl ammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212-7.
46. Koukoura O, Mantas N, Linardakis H, et al. Successful term pregnancy in a patient with Wegener's granulomatosis: case report and literature review. Fertil Steril. 2008;89(2):457.e1-5.
47. Miniero R, Tardivo I, Curtoni ES, et al. Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol. 2002;15(6):626-32.
48. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fi brosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156(6):1897-901.
49. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fi brosis. N Engl J Med. 2005;353(21):2229-42.
50. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-6.
51. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17(3):871-80.
52. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fi xed-dose concentrationcontrolled trial. Transplantation. 2008;86(8):1043-51.
53. Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007;18(6):1973-85.
54. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc. 2004;36(7):2068-70.
55. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391-6.
56. Fraile P, Garcia-Cosmes P, Martin P, et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. Transplant Proc. 2009;41(6):2433-4.
57. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 Suppl 3:iii28-31.
58. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-66.
59. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fi brosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-70.
60. Corte TJ, Ellis R, Renzoni EA, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specifi c interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):132-8.
61. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fi brosis. Chest. 1992;102(4):1090-4.
62. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835-44.
63. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90(6):401-9.
64. Martin-Suarez I, D'Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56(8): 481-7.
65. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018-27.
66. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-84.
67. Martin F, Lauwerys B, Lefebvre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 1997;6(3):254-7.
68. Janssen NM, Genta MS. The effects of immunosuppressive and anti-infl ammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160(5):610-9.
69. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am. 1997;23(1):149-67.
70. Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8(7):949-54.
71. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford). 2008;47(10):1506-9.
72. Dorr FA, Coltman Jr. CA. Second cancers following antineoplastic therapy. Curr Probl Cancer. 1985;9(2): 1-43.
73. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192-7.
74. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5 Suppl 1:S11-5.
75. Elder M, Rahman AM, McLay J. Early paracentral visual fi eld loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006;124(12):1729-33.
76. Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007;90(1):52-8.
77. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999; 140: 3-7.
78. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401-4.
79. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25(2):86-9.
80. Renault F, Flores-Guevara R, Renaud C, et al. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr. 2009;98(9):1500-3.
81. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997;91(1):31-9.
82. Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J. 2006;28(4):824-31.
83. Oliver SJ, Kikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102(3):225-36.
84. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227-32.
85. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50(2):235-41.
86. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1(3):194-205.
87. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fi brosis. Thorax. 2008;63(8):749.
88. Tilluckdharry L, Dean R, Farver C, et al. Thalidomiderelated eosinophilic pneumonia: a case report and brief literature review. Cases J. 2008;1(1):143.
89. Buttin BM, Moore MJ. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. Gynecol Oncol. 2008;111(3):546-8.
90. Younis TH, Alam A, Paplham P, et al. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol. 2003;121(1): 191-2.
91. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568-74.
92. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative effiffcacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33(12):2398-408.
93. Baughman RP, Drent M, Kavuru M, et al. Infl iximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802.
94. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177-85.
95. Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia. 2007;13:S47-50.
96. Raghu G, Fatenejad S, McDermott L. Effiffcacy and safety of etanercept in patients with idiopathic pulmonary fi brosis (IPF). Eur Respir J. 2006;28:767s.
97. Pham T, Claudepierre P, Deprez X, et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Infl ammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine. 2005;72 Suppl 1:S1-58.
98. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
99. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019.
100. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infl iximab, a tumor necrosis factoralpha neutralizing agent. N Engl J Med. 2001;345:1098-104.
101. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-5.
102. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756-61.
103. Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specifi c IFN-gamma assay. Ann Rheum Dis. 2008;67(1):84-90.
104. Dixon WG, Hyrich KL, Watson KD, et al. Drugspecifi c risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522-8.
105. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366-71.
106. Li S, Kaur PP, Chan V, et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infl iximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28(7):787-91.
107. Huang W, Cordoro KM, Taylor SL, et al. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008;58(6):970-7.
108. Furst DE. The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis. Semin Arthritis Rheum. 2010;39(5):327-46.
109. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infl iximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305-12.
110. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43(10):e95-100.
111. Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infl iximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8(4):R131.
112. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-51.
113. Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infl iximab therapy without methotrexate treatment. Rheumatol Int. 2009;30(2):275-6.
114. Daien CI, Monnier A, Claudepierre P, et al. Sarcoidlike granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883-6.
115. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35(3):537-44.
116. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602.
117. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infl iximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40.
118. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The signifi cance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86(2-3):123-30.
119. Rennard SI, Fogarty C, Kelsen S, et al. The Safety and Effiffcacy of Infl iximab in Moderate-To-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2007;175(9):926-34.
120. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352(4):351-61.
121. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infl iximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729-35.
122. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433-9.
123. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for infl ammatory arthritides. Arthritis Rheum. 2001;44(12):2862-9.
124. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379-84.
125. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66(4):490-7.
126. Katz JM, Bruno MK, Winterkorn JM, et al. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infl iximab. Arch Neurol. 2003;60(3):426-30.
127. Baughman RP, Bradley DA, Lower EE. Infl iximab for chronic ocular infl ammation. Int J Clin Pharmacol Ther. 2005;43:7-11.
128. El Mourabet M, El Hashem S, Harrison JR, et al. Anti-TNF antibody therapy for infl ammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets. 2010;11(2):234-41.
129. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76(1):28-34.
130. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36 (3): 635-41.
131. Kane S, Ford J, Cohen R, et al. Absence of infl iximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009;43(7):613-6.
132. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol. 2001;40(1):3-16.
133. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173(2):180-7.
134. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term effiffcacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913-20.
135. Leroux G, Costedoat-Chalumeau N, Brihaye B, et al. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. Arthritis Rheum. 2009;61(5):577-82.
136. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
137. Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and effiffcacy in a multicenter study. Med Oncol. 2001;18(2):141-8.
138. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999; 17(3):791-5.
139. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum. 2009;38(4):265-80.
140. Schwartzberg LS, Stepanski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16(4):393-8.
141. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456-73.
142. Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroidcontaining chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007;109(10): 4171-3.
143. Tuthill M, Crook T, Corbet T, et al. Rapid infusion of rituximab over 60 min. Eur J Haematol. 2009;82(4): 322-5.
144. Aksoy S, Dizdar O, Hayran M, et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50(3): 357-65.
145. Burr ML, Malaviya AP, Gaston JH, et al. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford). 2008;47(5):738-9.
146. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(7):1307-12.
147. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-40.
148. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225-8.
149. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virusinduced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49-73.
150. Baldo P, Cecco S, Giacomin E, et al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):647-65.
151. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140-51.
152. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44(8):769-86.
153. Rangan GK, Nguyen T, Mainra R, et al. Therapeutic role of sirolimus in non-transplant kidney disease. Pharmacol Ther. 2009;123(2):187-206.
154. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72(5):787-90.
155. Garrean S, Massad MG, Tshibaka M, et al. Sirolimusassociated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant. 2005;19(5):698-703.
156. Khalife WI, Kogoj P, Kar B. Sirolimus-induced alveolar hemorrhage. J Heart Lung Transplant. 2007;26(6):652-7.
157. Nocera A, Andorno E, Tagliamacco A, et al. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc. 2008;40(6):1950-2.
158. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fi brosis. Eur Respir J. 2010;36(3):695-6.
159. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fi brosis with a new antifi-brotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061-9.
160. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2005;171(9):1040-7.
161. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9.
162. Oku H, Shimizu T, Kawabata T, et al. Antifi brotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fi brosis. Eur J Pharmacol. 2008;590(1-3):400-8.
163. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary infl ammation by pirfenidone. Pulm Pharmacol Ther. 2003;16(4): 207-14.
164. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279-85.